Literature DB >> 21965756

Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis.

Wei Zhang1, Hsin-Chih Yang, Qi Wang, Zhi-Jun Yang, Hong Chen, Su-Mei Wang, Zhong-Mian Pan, Bu-Jian Tang, Qingdi Quentin Li, Li Li.   

Abstract

AIM: This study evaluated the clinical value of the combined detection of serum cathepsin L (CL), heparanase (Hpa), and matrix metalloproteinase-9 (MMP-9) for determining the degree of ovarian cancer invasion and metastasis before surgery. PATIENTS AND METHODS: Enzyme-linked immunosorbent assays were used to measure the serum content of CL, Hpa, and MMP-9 in 217 patients with untreated ovarian cancer before surgery, 100 patients with benign ovarian tumors, and 101 healthy women as controls. In addition, the degrees of invasion and metastasis were assessed by the 'gold standard' of clinicopathological diagnosis. The associations of the preoperative serum CL, Hpa, and MMP-9 levels with the clinicopathological factors and metastatic status were analyzed. Receiver operating characteristic (ROC) curve analysis was used to evaluate the usefulness of these markers for determining the degree of ovarian cancer invasion before surgery.
RESULTS: The serum CL, Hpa, and MMP-9 levels were significantly higher (p=0.001) in patients with malignant ovarian cancer compared with patients with benign ovarian tumors and healthy controls. The serum CL level was significantly higher in patients with epithelial ovarian carcinoma compared with non-epithelial ovarian carcinoma (p=0.048), whereas the serum levels of Hpa (p=0.109) and MMP-9 (p=0.544) did not differ significantly between these two groups. The serum CL, Hpa, and MMP-9 levels correlated with the degree of differentiation and the FIGO staging (p>0.05). The serum CL (p=0.030) and MMP-9 (p=0.010) levels were significantly associated with peritoneal metastasis, and the serum Hpa level (p=0.042) was associated with distant metastasis. A ROC curve analysis revealed sensitivity of 60.9%, 69.6%, and 72.2%, and specificity of 57.4%, 67.2%, and 68.9% for the preoperative serum levels of CL, Hpa, and MMP-9, respectively, as tumor markers for the degree of extra-pelvic metastasis.
CONCLUSION: Elevated serum CL, Hpa, and MMP-9 levels are correlated with malignant invasion and progression in ovarian cancer. The combined detection of serum CL, Hpa, and MMP-9 may be useful for determining the extent of ovarian cancer metastasis before surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21965756

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  19 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Expression and correlation of matrix metalloproteinase-9 and heparanase in patients with breast cancer.

Authors:  Dabei Tang; Ying Piao; Shu Zhao; Xudong Mu; Shuo Li; Wenjie Ma; Ying Song; Jingxuan Wang; Wenhui Zhao; Qingyuan Zhang
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

3.  Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo.

Authors:  Chao Zeng; Zun-Fu Ke; Wei-Ren Luo; Yun-Hong Yao; Xin-Rong Hu; Wei Jie; Jin-Bao Yin; Shi-Jun Sun
Journal:  Med Oncol       Date:  2013-01-04       Impact factor: 3.064

4.  Over-expression of VEGF and MMP-9 in residual tumor cells of hepatocellular carcinoma after embolization with lipidol.

Authors:  Yu-Long Shi; Tao Xu; Le-Ping Li; Xiao-Ping Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

5.  Dual-Mechanism Quenched Fluorogenic Probe Provides Selective and Rapid Detection of Cathepsin L Activity*.

Authors:  Kelton A Schleyer; Ben Fetrow; Peter Zannes Fatland; Jun Liu; Maya Chaaban; Biwu Ma; Lina Cui
Journal:  ChemMedChem       Date:  2021-01-15       Impact factor: 3.466

6.  Cancer-associated mutations reveal a novel role for EpCAM as an inhibitor of cathepsin-L and tumor cell invasion.

Authors:  Narendra V Sankpal; Taylor C Brown; Timothy P Fleming; John M Herndon; Anusha A Amaravati; Allison N Loynd; William E Gillanders
Journal:  BMC Cancer       Date:  2021-05-12       Impact factor: 4.430

7.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

8.  Diagnosis and management of peritoneal metastases from ovarian cancer.

Authors:  Evgenia Halkia; John Spiliotis; Paul Sugarbaker
Journal:  Gastroenterol Res Pract       Date:  2012-07-19       Impact factor: 2.260

9.  Calprotectin: a novel biomarker for the diagnosis of pleural effusion.

Authors:  N Sánchez-Otero; S Blanco-Prieto; M Páez de la Cadena; L Vázquez-Iglesias; A Fernández-Villar; M I Botana-Rial; F J Rodríguez-Berrocal
Journal:  Br J Cancer       Date:  2012-10-23       Impact factor: 7.640

10.  Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening.

Authors:  Alexandros Laios; Bashir M Mohamed; Lynn Kelly; Richard Flavin; Stephen Finn; Lynda McEvoy; Michael Gallagher; Cara Martin; Orla Sheils; Martina Ring; Anthony Davies; Margaret Lawson; Noreen Gleeson; Tom D'Arcy; Charles d'Adhemar; Lucy Norris; Ream Langhe; Feras Abu Saadeh; John J O'Leary; Sharon A O'Toole
Journal:  Int J Mol Sci       Date:  2013-01-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.